Enterprise Development Holdings Limited, through its indirect wholly-owned subsidiary, has taken a significant step in the biomedical industry by acting as the sole managing partner of Qitong Fuyuan. The subsidiary has invested RMB120 million in Hainan Yayi Partnership, which recently acquired a 14.16% equity interest in the biomedicine-focused company 赛隆药业集团股份有限公司. This acquisition, valued at RMB199 million, marks a strategic move for Enterprise Development Holdings Limited in expanding its presence in the medical research and development sector. The transaction involved the company's participation in investment activities and asset management services within the biomedical field, particularly excluding human stem cells and gene diagnosis.